Eli Lilly and Company
893 S Delaware St
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2188 articles with Eli Lilly and Company
Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients
Over Half of Patients Treated with Tanezumab Reported a 50 Percent or Greater Reduction in Osteoarthritis Pain of the Knee or Hip
Mesothelioma is a rare cancer that develops in the lining of the lungs, abdomen, or cardiovascular cavity. A 2017 study reported that the number of people affected by this rare cancer is between 2,400 - 2,800 individuals per year in the United States alone.
10/22/2018Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.
ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
Integrated safety analysis reflects long-term results from 3,492 treated patients for 7,860 patient-years of exposure
10/17/2018The Minnesota Attorney General is calling out Sanofi-Aventis, Novo Nordisk and Eli Lilly over alleged price gouging for insulin. This week Minnesota Attorney General Lori Swanson filed a lawsuit against the three companies over insulin price hikes.
With a new wave of migraine medications now on the market from multiple drugmakers that block the calcitonin gene-related peptide receptor (CGRP-R), Express Scripts has chosen to back two medications and exclude a third from the list of drugs it will carry.
As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Compliance Committee.
“President Trump is taking historic action to bring patients more transparency through consumer advertising,” Azar said in a speech. “We are proposing to require American drug companies for the first time ever to include in their TV advertising the list prices of drugs paid for by Medicare or Med...
New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
Forty-one abstracts supporting Taltz® and Olumiant® reveal new data including findings in ankylosing spondylitis (radiographic axial spondyloarthritis), psoriatic arthritis, systemic lupus erythematosus and rheumatoid arthritis
Company advancing novel platform technologies to enable non-invasive, targeted regulation of neuronal cell activity.
- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common stock
Lilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC
National survey uncovers majority of people living with MBC say the daily stress and anxiety they experience associated with the disease can impact everything from relationships to careers, with many experiencing mental health conditions
ADOCIA announces that Eli Lilly and Company (“Lilly”) filed a complaint against Adocia in the United States District Court of the Southern District of Indiana on October 9th, 2018.
New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care
Data from abemaciclib, pemetrexed and ramucirumab late-stage clinical development programs in multiple difficult-to-treat tumor types
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment
Boehringer Ingelheim and Eli Lilly released data from their Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III trial in type 1 diabetes.
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar reduction and weight loss in people with type 2 diabetes.
Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2018 on Tuesday, November 6, 2018.